whether inhaled tiotropium and ipratropium increase stroke, heart attack, and death in COPD patients

Experts are debating whether inhaled tiotropium and ipratropium increase stroke, heart attack, and death in COPD patients.

The lay press has picked up on a recent meta-analysis linking tiotropium (Spiriva) and ipratropium (Atrovent, Combivent) to a higher risk of cardiovascular events.

But don't jump to conclusions. There are two sides to the story.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote